06 March 2020 – Funded FDA to support development and review of vaccines

This item is sourced from COVID-19 Policy Watch co-ordinated by Policy. We are in the process of gathering further information and aligning taxonomies for these items.

Type of Intervention: Medical products and medicines
Sectors Involved:
Level of Jurisdiction: Federal
Lead People/Agency:

Overview: The U.S. Congress funded $61 million for the Food and Drug Administration (FDA) to support the development and review of vaccines and other countermeasures, as well as for monitoring and mitigating shortages to medical supply chains, as part of phase 1 legislation.

Phase 3 legislation provided an additional $11 billion for coronavirus vaccines, treatment, and diagnostics and an additional $80 million for the FDA to prioritize and expedite approval of coronavirus drugs.
Full details here: https://www.rpc.senate.gov/policy-papers/update-on-coronavirus-response